Molecular subtyping of breast cancer improves identification of both high and low risk patients

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.
   PubMed Web of Science ®Google Scholar
• Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2003;95:1482–1485.
   PubMed Web of Science ®Google Scholar
• Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–752.
   PubMed Web of Science ®Google Scholar
• Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869–10874.
   PubMed Web of Science ®Google Scholar
• Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100:8418–8423.
   PubMed Web of Science ®Google Scholar
• Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA. 2003;100:10393–10398.
   PubMed Web of Science ®Google Scholar
• Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27:1160–1167.
   PubMed Web of Science ®Google Scholar
• Curtis C, Shah SP, Chin SF, et al. The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups. Nature. 2012;486:346–352.
   PubMed Web of Science ®Google Scholar
• Guedj M, Marisa L, de RA, et al. A refined molecular taxonomy of breast cancer. Oncogene. 2012;31:1196–1206.
   PubMed Web of Science ®Google Scholar
• Cardoso F, van't Veer LJ, Bogaerts J, et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016;375:717–729.
   PubMed Web of Science ®Google Scholar
• Dowsett M, Sestak I, Lopez-Knowles E, et al. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol. 2013;31:2783–2790.
   PubMed Web of Science ®Google Scholar
• van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999–2009.
   PubMed Web of Science ®Google Scholar
• Sparano JA, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol. 2008;26:721–728.
   PubMed Web of Science ®Google Scholar
• Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817–2826.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70.
   PubMed Web of Science ®Google Scholar
• Farmer P, Bonnefoi H, Becette V, et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene. 2005;24:4660–4671.
   PubMed Web of Science ®Google Scholar
• Smid M, Wang Y, Zhang Y, et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 2008;68:3108–3114.
   PubMed Web of Science ®Google Scholar
• Prat A, Pineda E, Adamo B, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 2015;24(Suppl 2):S26–S35.
   PubMed Web of Science ®Google Scholar
• Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies–improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015;26:1533–1546.
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24:2206–2223.
   PubMed Web of Science ®Google Scholar
• Prat A, Cheang MC, Martin M, et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol. 2013;31:203–209.
   PubMed Web of Science ®Google Scholar
• Viale G, Regan MM, Maiorano E, et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol. 2007;25:3846–3852.
   PubMed Web of Science ®Google Scholar
• Prat A, Parker JS, Fan C, et al. PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer. Breast Cancer Res Treat. 2012;135:301–306.
   PubMed Web of Science ®Google Scholar
• Christiansen P, Bjerre K, Ejlertsen B, et al. Mortality rates among early-stage hormone receptor-positive breast cancer patients: a population-based cohort study in Denmark. J Natl Cancer Inst. 2011;103:1363–1372.
   PubMedGoogle Scholar
• Ejlertsen B, Tuxen MK, Jakobsen EH, et al. Adjuvant cyclophosphamide and docetaxel with or without epirubicin for early TOP2A-normal breast cancer: DBCG 07-rEAD, an open-label, phase III, randomized trial. J Clin Oncol. 2017;35:2639–2646.
   PubMed Web of Science ®Google Scholar
• Ejlertsen B, Jensen MB, Mouridsen HT. Excess mortality in postmenopausal high-risk women who only receive adjuvant endocrine therapy for estrogen receptor positive breast cancer. Acta Oncol. 2014;53:174–185.
   PubMed Web of Science ®Google Scholar
• Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2007;8:118–127.
   PubMed Web of Science ®Google Scholar
• Leek JT, Johnson WE, Parker HS, et al. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics. 2012;28:882–883.
   PubMed Web of Science ®Google Scholar
• Vikesa J, Moller AK, Kaczkowski B, et al. Cancers of unknown primary origin (CUP) are characterized by chromosomal instability (CIN) compared to metastasis of know origin. BMC Cancer. 2015;15:151.
   PubMed Web of Science ®Google Scholar
• Lakhani SR, Ellis IO, Schnitt SJ, et al. WHO Classification of Tumors of the Breast. IARC: Lyon; 2012.
   Google Scholar
• Rossing HH, Talman ML, Laenkholm AV, et al. Implementation of TMA and digitalization in routine diagnostics of breast pathology. APMIS. 2012;120:341–347.
   PubMed Web of Science ®Google Scholar
• Hansen TV, Vikesaa J, Buhl SS, et al. High-density SNP arrays improve detection of HER2 amplification and polyploidy in breast tumors. BMC Cancer. 2015;15:35.
   PubMed Web of Science ®Google Scholar
• Jonson L, Ahlborn LB, Steffensen AY, et al. Identification of six pathogenic RAD51C mutations via mutational screening of 1228 Danish individuals with increased risk of hereditary breast and/or ovarian cancer. Breast Cancer Res Treat. 2016;155:215–222.
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131:18–43.
   PubMed Web of Science ®Google Scholar
• Thor AD, Liu S, Moore DH, et al. Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer. J Clin Oncol. 1999;17:470–477.
   PubMed Web of Science ®Google Scholar
• Viale G. Pathological work up of the primary tumor: getting the proper information out of it. Breast. 2011;20(Suppl 3):S82–S86.
   PubMed Web of Science ®Google Scholar
• van 't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530–536.
   PubMed Web of Science ®Google Scholar
• Greytak SR, Engel KB, Bass BP, et al. Accuracy of molecular data generated with FFPE biospecimens: lessons from the literature. Cancer Res. 2015;75:1541–1547.
   PubMed Web of Science ®Google Scholar
• Williams PM, Li R, Johnson NA, et al. A novel method of amplification of FFPET-derived RNA enables accurate disease classification with microarrays. J Mol Diagn. 2010;12:680–686.
   PubMed Web of Science ®Google Scholar
• Mittempergher L, de Ronde JJ, Nieuwland M, et al. Gene expression profiles from formalin fixed paraffin embedded breast cancer tissue are largely comparable to fresh frozen matched tissue. PLoS One. 2011;6:e17163.
   PubMed Web of Science ®Google Scholar
• Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287–5312.
   PubMed Web of Science ®Google Scholar
• Yerushalmi R, Woods R, Ravdin PM, et al. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010;11:174–183.
   PubMed Web of Science ®Google Scholar
• Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101:736–750.
   PubMed Web of Science ®Google Scholar
• Prat A, Parker JS, Karginova O, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010;12:R68.
   PubMed Web of Science ®Google Scholar
• Lakhani SR, Reis-Filho JS, Fulford L, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res. 2005;11:5175–5180.
   PubMed Web of Science ®Google Scholar
• Southey MC, Park DJ, Nguyen-Dumont T, et al. COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration. Breast Cancer Res. 2013;15:402.
   PubMed Web of Science ®Google Scholar